

**Supplemental Table 1 – International Classification of Diseases (ICD) Codes Used to Identify Inflammatory Bowel Disease**

	<b>ICD-9</b>	<b>ICD-10</b>
<b>Ulcerative Colitis</b>	556.0, 556.1, 556.2, 556.3, 556.4, 556.5, 556.6, 556.8, 556.9	K51.00, K51.011, K51.012, K51.013, K51.014, K51.018, K51.019, K51.20, K51.211, K51.212, K51.213, K51.214, K51.218, K51.219, K51.30, K51.311, K51.312, K51.313, K51.314, K51.318, K51.319, K51.40, K51.411, K51.412, K51.413, K51.414, K51.418, K51.419, K51.50, K51.511, K51.512, K51.513, K51.514, K51.518, K51.519, K51.80, K51.811, K51.812, K51.813, K51.814, K51.818, K51.819, K51.90, K51.911, K51.912, K51.913, K51.914, K51.918, K51.919
<b>Crohn's Disease</b>	555.0, 555.1, 555.2, 555.9	K50.00, K50.011, K50.012, K50.013, K50.014, K50.018, K50.019, K50.10, K50.111, K50.112, K50.113, K50.114, K50.118, K50.119, K50.80, K50.811, K50.812, K50.813, K50.814, K50.818, K50.819, K50.90, K50.911, K50.912, K50.913, K50.914, K50.918, K50.919

**Supplemental Table 2 – Sensitivity Analysis of Mixed-Effects Cox Regression Model for SARS-CoV2 Infection\*† with Relaxed Exclusion Criteria**

Variable	Hazard Ratio	95% Confidence Interval	p-value
Age (per year)	0.99	(0.99 - 1.00)	0.001
<b>Race</b>			
White	(ref)		
Black	1.51	(1.24 - 1.85)	<0.001
Hispanic	1.23	(0.86 - 1.75)	0.26
Other	1.60	(1.15 - 2.21)	0.005
<b>Diabetes Mellitus</b>	1.44	(1.20 - 1.72)	<0.001
<b>Peripheral Vascular Disease</b>	1.78	(1.32 - 2.39)	<0.001
<b>Obesity</b>	1.35	(1.10 - 1.65)	0.004
<b>Corticosteroid Use</b>	1.60	(1.23 - 2.08)	<0.001
<b>IBD Med Category</b>			
5-ASA	(ref)		
Thiopurine	1.03	(0.76 - 1.40)	0.84
Anti-TNF	1.14	(0.89 - 1.45)	0.31
Anti-TNF + TP	1.24	(0.85 - 1.79)	0.26
Anti-TNF + MTX	0.93	(0.49 - 1.76)	0.82
Vedolizumab	1.70	(1.16 - 2.48)	0.006
No IBD Meds	0.94	(0.78 - 1.13)	0.52

\* United States geographic region is treated as a random effect

† The following variables were not retained in final multivariable models on the basis of  $p > 0.05$  or non-minimization of Bayesian Information Criterion in associated models: sex, inflammatory bowel disease diagnosis, hypertension, heart failure, arrhythmia, chronic obstructive pulmonary disease, renal failure

**Supplemental Table 3 – Sensitivity Analysis for Development of SARS-CoV2 Infection using Fine and Gray Competing Risks Regression\***

<b>Variable</b>	<b>Subhazard Ratio</b>	<b>95% Confidence Interval</b>	<b>p-value</b>
<b>Age (per year)</b>	0.99	(0.99 - 1.00)	0.001
<b>Race</b>			
White	(ref)		
Black	1.47	(1.20 - 1.81)	<0.001
Hispanic	1.21	(0.85 - 1.71)	0.29
Other	1.50	(1.07 - 2.10)	0.02
<b>Diabetes Mellitus</b>	1.43	(1.19 - 1.73)	<0.001
<b>Peripheral Vascular Disease</b>	1.70	(1.26 - 2.31)	0.001
<b>Obesity</b>	1.30	(1.05 - 1.61)	0.02
<b>Corticosteroid Use</b>	1.56	(1.19 - 2.03)	0.001
<b>IBD Med Category</b>			
5-ASA alone	(ref)		
Thiopurine	1.05	(0.77 - 1.43)	0.75
Anti-TNF	1.14	(0.89 - 1.46)	0.31
Anti-TNF + TP	1.26	(0.87 - 1.83)	0.22
Anti-TNF + MTX	0.90	(0.48 - 1.72)	0.76
Vedolizumab	1.69	(1.16 - 2.48)	0.007
No IBD Meds	1.01	(0.83 - 1.23)	0.92

\* *Death from any non-COVID-19-related cause was treated as a competing event*